Skip to main
  1. Stocks
  2. Hemab Therapeutics Holdings Inc
  3. Forecast
COAG

COAG Stock Forecast & Price Target

COAG Analyst Ratings

Based on 8 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Hemab Therapeutics Hldgs is supported by a de-risked lead asset in sutacimig, where FDA endorsement of the data package clears a path to a 2H26 pivotal Phase 3 in GT after Phase 2 LTE data in 34 participants showed sustained bleed reduction, a 62% drop in mean high-intensity ATBR, and no Grade >3 related events. The company’s second pillar, HMB-002, adds meaningful pipeline breadth with dose-proportionate PK/PD, ≥2.4-fold VWF and FVIII increases, normalization of thrombin generation and APTT, and 8/9 evaluable patients recording zero treated bleeds over 28 days, while HMB-003 expands optionality into heavy menstrual bleeding with differentiated once-per-cycle SC antifibrinolytic potential. Financially, Hemab ended 2Q26 with $457.5M in cash and equivalents against 2Q26 operating expenses of $26.1M and EPS of ($0.80), suggesting runway into 2030 while advancing multiple clinical catalysts.

Bears say

Hemab Therapeutics Hldgs is a clinical-stage biotechnology company whose valuation is highly exposed to binary development risk, with the biggest near-term concern being poorer-than-expected clinical results or failure of sutacimig, HMB-001, or HMB-002 to receive FDA approval in their respective indications. Because its pipeline is concentrated in prophylactic therapies for bleeding disorders such as Glanzmann thrombasthenia, Factor VII deficiency, and von Willebrand disease, setbacks in any one program could materially weaken the company’s fundamental outlook and limit commercial optionality. Competitive pressure from better-than-expected rival products and the possibility of unfavorable reimbursement further threaten future adoption and economics, making execution risk especially elevated for a company with no diversified operating base beyond research and development.

COAG has been analyzed by 8 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Hemab Therapeutics Holdings Inc and is not a guaranteed prediction by Public.com or investment advice.

COAG Analyst Forecast & Price Prediction

Get the latest COAG stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in COAG

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Hemab Therapeutics Holdings Inc (COAG) Forecast

Analysts have given COAG a Buy based on their latest research and market trends.

According to 8 analysts, COAG has a Buy consensus rating as of Nov 20, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $56, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $56, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Hemab Therapeutics Holdings Inc (COAG)


COAG Analyst Forecast & Price Prediction

Get the latest COAG stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in COAG

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover COAG stock data and trends